Sugi Predict

Sugi Predict / Targets / PIK3CA

PIK3CA

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform · P42336 · PIK3CA on Sugi Atlas →

437,133 patent compounds predicted against PIK3CA, 224,256 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL7050 SCHEMBL7050 1.00 20/20
SCHEMBL7052 SCHEMBL7052 1.00 20/20
SCHEMBL7070 SCHEMBL7070 1.00 20/20
SCHEMBL7166 SCHEMBL7166 1.00 20/20
SCHEMBL7186 SCHEMBL7186 1.00 20/20
SCHEMBL7257 SCHEMBL7257 1.00 20/20
SCHEMBL7283 SCHEMBL7283 1.00 20/20
SCHEMBL7291 SCHEMBL7291 1.00 20/20
SCHEMBL7499 SCHEMBL7499 1.00 20/20
SCHEMBL7530 SCHEMBL7530 1.00 20/20
SCHEMBL7558 SCHEMBL7558 1.00 20/20
SCHEMBL7575 SCHEMBL7575 1.00 20/20
SCHEMBL7603 SCHEMBL7603 1.00 20/20
SCHEMBL7607 SCHEMBL7607 1.00 20/20
SCHEMBL7619 SCHEMBL7619 1.00 20/20
SCHEMBL7633 SCHEMBL7633 1.00 20/20
SCHEMBL7659 SCHEMBL7659 1.00 20/20
SCHEMBL7693 SCHEMBL7693 1.00 20/20
SCHEMBL7700 SCHEMBL7700 1.00 20/20
SCHEMBL7728 SCHEMBL7728 1.00 20/20

Clinical trials — most relevant to PIK3CA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway PHASE3NOT_YET_RECRUITING
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4 PHASE2NOT_YET_RECRUITING
Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive PHASE2COMPLETED
NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer PHASE2COMPLETED
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) PHASE2COMPLETED
Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer PHASE2COMPLETED
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) PHASE2COMPLETED
AZD8186 and Paclitaxel in Advanced Gastric Cancer PHASE1/PHASE2UNKNOWN
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors PHASE1COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules PHASE1COMPLETED
PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic PHASE1COMPLETED
Partial PTEN Deletion in Breast Cancer nanUNKNOWN
PIK3CA Mutational Status Assessment nanRECRUITING
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN
PIK3CA in HER2+ BC and pCR Trial nanUNKNOWN
Studying Tumor Tissue Samples From Patients With Early-Stage Breast Cancer nanWITHDRAWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Compassionate Use of BYL 719 Alpelisib nanNO_LONGER_AVAILABLE
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane nanUNKNOWN
Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma nanUNKNOWN
Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib nanCOMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PIK3CA binder may also engage these)

ProteinNameSimilarity
A0A0G2K344 — 1.000 A0A0G2K344 →
P32871 — 1.000 P32871 →
P42337 — 1.000 P42337 →
Q8BTI9 — 1.000 Q8BTI9 →
Q9Z1L0 — 1.000 Q9Z1L0 →
PIK3CB Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform 0.999 landscape →
O02697 — 0.999 O02697 →
P42348 — 0.997 P42348 →
Q9JHG7 — 0.996 Q9JHG7 →
PIK3CD Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform 0.995 landscape →
Q5D891 — 0.995 Q5D891 →
Q6AZN6 — 0.994 Q6AZN6 →
PIK3C3 Phosphatidylinositol 3-kinase catalytic subunit type 3 0.994 landscape →
P42339 — 0.993 P42339 →
PIK3CG Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform 0.993 landscape →
O88763 — 0.993 O88763 →
Q6PF93 — 0.992 Q6PF93 →
O35904 — 0.992 O35904 →
B4NBB0 — 0.990 B4NBB0 →
P50520 — 0.989 P50520 →
P42347 — 0.989 P42347 →
B0XDC4 — 0.989 B0XDC4 →
Q7Z392 — 0.988 Q7Z392 →
G5EF51 — 0.988 G5EF51 →
P70600 — 0.988 P70600 →
Q86T65 — 0.988 Q86T65 →
B2RXC1 — 0.988 B2RXC1 →
PTK2B Protein-tyrosine kinase 2-beta 0.987 landscape →
A6N6J5 — 0.987 A6N6J5 →
Q9TTH8 — 0.987 Q9TTH8 →